Intellia Therapeutics, Inc. (NTLA)

NasdaqGM • Currently down 0.48 (-4.03%) in today's trading session

2 members of Congress have disclosed 20 trades in Intellia Therapeutics, Inc. (NTLA) via STOCK Act filings. The most recent disclosure was a sale by Donald S. Beyer on 28 February 2022. The most active traders have been Donald S. Beyer (19) and Donald Sternoff Beyer Jr (1). Aggregate disclosed activity totals roughly $96K in purchases and $88.5K in sales (midpoint estimates from bracketed disclosure amounts).

Intellia Therapeutics, Inc. is currently trading at $11.43, positioned at 17% of its 52-week range ($7.95 – $28.25).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$11.43
24h Change
-0.48 (-4.03%)
52 Week Range
$7.95–$28.25
View on NASDAQ

Intellia Therapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for NTLA

Select to highlight on chart
5 transactions
Compliance: 50%
Donald S. Beyer28 Feb 20223 Mar 2022SaleStock$15,001 - $50,000N/A
Donald S. Beyer29 Oct 202130 Oct 2021SaleStock$1,001 - $15,000N/A
Donald S. Beyer20 Sept 20211 Oct 2021SaleStock$1,001 - $15,000N/A
Donald S. Beyer21 Jul 20217 Aug 2021SaleStock$1,001 - $15,000N/A
Donald S. Beyer15 Jan 202131 Jan 2021SaleStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$1.6B

Volume

5.43M

Beta

1.80

P/E Ratio

-3.40

Fundamentals

EPS

$-3.36

Div. Yield

-

Open

$11.82

Day Range

$11.29 – $11.87

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
John Leonard
IPO Date
2016-05-06
Website
www.intelliatx.com

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently...

Earnings

Next Report

Q3 2026

5 Nov

EPS Est.

$-0.80

Rev. Est.

$9.7M

Days Until

21

Recent Quarters

Q2 20266 Aug
EPS$-0.80
Miss 0.1%
Q1 202611 May
EPS$-0.81
Beat 12.0%
Q4 202526 Feb
EPS$-0.83
Beat 16.2%
Q3 20256 Nov
EPS$-0.92
Beat 9.8%
Q2 20257 Aug
EPS$-0.99
Beat 3.9%
Q1 20258 May
EPS$-1.10
Beat 12.7%
Q4 202427 Feb
EPS$-1.24
Beat 6.1%
Q3 20247 Nov
EPS$-1.34
Beat 2.2%
Q2 20248 Aug
EPS$-1.31
Miss 8.3%
Q1 20249 May
EPS$-1.06
Beat 21.5%
Q4 202322 Feb
EPS$-1.46
Beat 0.7%
Q3 20239 Nov
EPS$-1.38
Beat 9.2%
Q2 20233 Aug
EPS$-1.40
Miss 6.1%
Q1 20234 May
EPS$-1.17
Beat 17.0%
Q4 202223 Feb
EPS$-1.40
Beat 0.0%
Q3 20223 Nov
EPS$-1.49
Miss 13.7%
Q2 20224 Aug
EPS$-1.33
Miss 1.5%
Q1 20225 May
EPS$-1.96
Miss 76.6%
Q4 202124 Feb
EPS$-1.09
Miss 19.8%
Q3 20214 Nov
EPS$-0.97
Miss 14.1%
Q2 20215 Aug
EPS$-1.01
Miss 65.6%
Q1 20216 May
EPS$-0.69
Miss 4.5%
Q4 202025 Feb
EPS$-0.69
Miss 21.1%
Q3 20205 Nov
EPS$-0.47
Beat 13.0%
Q2 20206 Aug
EPS$-0.61
Beat 11.6%
Q1 20207 May
EPS$-0.63
Miss 61.5%
Q4 201927 Feb
EPS$-0.57
Miss 5.6%
Q3 201931 Oct
EPS$-0.49
Beat 19.7%
Q2 20191 Aug
EPS$-0.56
Beat 8.2%
Q1 20192 May
EPS$-0.49
Beat 7.5%
Q4 201827 Feb
EPS$-0.43
Beat 21.8%
Q3 201831 Oct
EPS$-0.53
Miss 10.4%
Q2 20181 Aug
EPS$-0.52
Beat 8.8%
Q1 20181 May
EPS$-0.51
Beat 8.9%
Q4 201714 Mar
EPS$-0.61
Miss 27.1%
Q3 201731 Oct
EPS$-0.44
Beat 10.2%
Q2 20171 Aug
EPS$-0.45
Miss 7.1%
Q1 20172 May
EPS$-0.36
Miss 5.9%
Q4 201614 Mar
EPS$-0.31
Miss 29.2%
Q3 20161 Nov
EPS$-0.22
Beat 4.3%
Q2 20164 Aug
EPS$-0.36
Miss 260.0%
Q1 20163 Jun
EPS$-9.89
Miss 3432.1%
Q1 20166 May
EPS$-0.30
Q2 201530 Sept
EPS$-0.17
Q1 201530 Jun
EPS$-0.17
Q4 201431 Mar
EPS$-0.06
Q3 201431 Dec
EPS$-2.48
Q1 201430 Jun
EPS$-0.06

5 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

NVS

Novartis AG

47
$146.88+4.47 (+3.14%)
Healthcare
Held by same politician
Same sector: Healthcare
1 politician
View Stock

NVDA

NVIDIA Corporation

22
$221.30-7.22 (-3.16%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

AAPL

Apple Inc.

17
$342.96+1.69 (+0.50%)
Technology
Held by same politician
1 politician
View Stock

Frequently Asked Questions about NTLA

Which members of Congress have traded NTLA?
2 members of Congress have disclosed 20 trades in Intellia Therapeutics, Inc. (NTLA) under the STOCK Act. The most active traders are Donald S. Beyer and Donald Sternoff Beyer Jr.
When was NTLA most recently disclosed by Congress?
The most recent NTLA disclosure was a sale by Donald S. Beyer on 28 February 2022.
What is the total disclosed congressional trading volume for NTLA?
Members of Congress have disclosed approximately $96K in NTLA purchases and $88.5K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in NTLA?
This NTLA page updates as soon as new STOCK Act disclosures are filed for Intellia Therapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.